Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  DAIICHI SANKYO COMPANY, LIMITED    4568   JP3475350009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Daiichi Sankyo Co : Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/24/2012 | 07:59am CEST

For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges) Please address inquiries to Toshiaki Sai, General Manager, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Daiichi Sankyo to Develop Narcotic Analgesic Hydromorphone Hydrochloride in Japan Tokyo, Japan (March 23, 2012) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it will develop hydromorphone hydrochloride, a narcotic analgesic that has yet to be approved in Japan.

Hydromorphone hydrochloride is an opiate, narcotic analgesic that has been available outside of Japan for over 80 years. Although it is the standard for pain management for cancer pain treatment according to WHO guidelines, hydromorphone hydrochloride has yet to be approved in Japan.
Mundipharma K.K. had been requested by the Study Group on Unapproved and Off-label Drugs of High Medical Need* to develop hydromorphone hydrochloride in Japan, but after subsequent discussions it was decided that Daiichi Sankyo would develop the drug instead. The development of hydromorphone hydrochloride will contribute to the improvement of pain management options in Japan, and Daiichi Sankyo, through its commitment to corporate social responsibility, will continue to work to make unapproved and off-label drugs available in Japan in order to further contribute to medical treatment options for patients.
*A study group set up by Japan's Ministry of Health, Labour and Welfare to promote development by pharmaceutical companies of unapproved and off-label drugs in Japan that have been approved in the United States and Europe.
###

distributed by

This press release was issued by Daiichi Sankyo Co. Ltd. and was initially posted at http://www.daiichisankyo.com/news/20120321_376_E2.pdf . It was distributed, unedited and unaltered, by noodls on 2012-03-24 07:53:56 AM. The issuer is solely responsible for the accuracy of the information contained therein.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on DAIICHI SANKYO COMPANY, LI
08/17 DAIICHI SANKYO : New Cancer Research Study Results from Daiichi Sankyo Described..
08/11 COHERUS BIOSCIENCES, INC. (NASDAQ : CHRS) Files An 8-K Termination of a Material..
08/10 Patent Issued for Crystals of Dispiropyrrolidine Derivatives (USPTO 9718830)
08/10 DAIICHI SANKYO : Announces Settlement Agreement on U.S. Products Liability Litig..
08/10 ROCHE : Daiichi`s Plexxikon goes after Novartis cancer med Tafinlar in BRAF pate..
08/10 DAIICHI SANKYO : Moves supreme court to block singh brothers fortis stake sale
08/02 DAIICHI SANKYO : Announces Settlement Agreement on U.S. Products Liability Litig..
08/02 DAIICHI SANKYO : Benicar Users Reach $300 Million Settlement with Daiichi Sankyo..
07/29 Zenotech Laboratories share zooms 5% as Sun Pharmaceuticals raises stake
07/27 ZYMEWORKS : and Daiichi Sankyo Announce Successful Achievement of a Research Mil..
More news
News from SeekingAlpha
08/11 Coherus and Daiichi Sankyo terminate Enbrel biosimilar project
08/10 HealthSouth Invades Big Pharma Duet To Place Atop 'Safer' Dividend Healthcare..
08/05 Daiichi Sankyo Company's (DSKYF) Management on Q1 2018 Results - Earnings Cal..
07/31 Clementia Pharmaceuticals Readies $100 Million IPO
07/31 Daiichi Sankyo Co. reports Q1 results
Financials ( JPY)
Sales 2018 922 162 M
EBIT 2018 -
Net income 2018 68 326 M
Finance 2018 361 902 M
Yield 2018 2,97%
P/E ratio 2018 22,93
P/E ratio 2019 25,56
EV / Sales 2018 1,42x
EV / Sales 2019 1,54x
Capitalization 1 669 367 M
Chart DAIICHI SANKYO COMPANY, LI
Duration : Period :
DAIICHI SANKYO COMPANY, LI Technical Analysis Chart | 4568 | JP3475350009 | 4-Traders
Technical analysis trends DAIICHI SANKYO COMPANY, LI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 2 512  JPY
Spread / Average Target 6,7%
EPS Revisions
Managers
NameTitle
Joji Nakayama President, CEO & Representative Director
Kentaro Takamura IR Contact, Manager-Finance & Accounting
Glenn J. Gormley Senior Managing Executive Officer, Head-R&D
Masahiko Ohtsuki Executive Officer & Senior Manager-Research
Kazunori Hirokawa Representative Director, VP & GM-Administration
Sector and Competitors
1st jan.Capitalization (M$)
DAIICHI SANKYO COMPANY, LIMITED-1.53%15 200
JOHNSON & JOHNSON15.77%360 112
NOVARTIS10.12%220 515
ROCHE HOLDING LTD.5.33%218 264
PFIZER2.71%198 663
MERCK AND COMPANY6.51%171 005